

# **cf**benchmarks

CME CF Cryptocurrency Pricing Products  
Oversight Committee

Founding Charter

Version: 4

Version Date: 20<sup>th</sup> May 2020

**Contents**

**Version History** ..... Error! Bookmark not defined.

**Purpose** ..... Error! Bookmark not defined.

**Oversight Committee Meetings, Tasks and Authority** ..... Error! Bookmark not defined.

**Appendix A**..... Error! Bookmark not defined.

## Version History

<b>Version</b>	<b>Version Date</b>	<b>Changes to Previous</b>
<b>1</b>	<b>Nov 11<sup>th</sup> 2016</b>	<b>N/A</b>
<b>1.1</b>	<b>June 7<sup>th</sup> 2018</b>	<b>In scope reference rates and real time indices expanded</b>  <b>Generalised wording to support expanded number of reference rates and real time indices</b>  <b>Appendix of in scope reference rates and indices added</b>  <b>Disclaimer added</b>
<b>2</b>	<b>12<sup>th</sup> July 2019</b>	<b>Rebrand to CF Benchmarks</b>
<b>3</b>	<b>11<sup>th</sup> September 2019</b>	<b>Update legal text with BMR registration</b>
<b>4</b>	<b>20<sup>th</sup> May 2020</b>	<b>Update copyright year</b>

## Purpose

This Cryptocurrency Pricing Products Oversight Committee (the “**Oversight Committee**”) has been established jointly by CF Benchmarks Ltd. (“**CF**”) and Chicago Mercantile Exchange Inc. (“**CME**”). The Oversight Committee has been established as part of the governance arrangements relating to the offering of **Cryptocurrency Pricing Products**, (for a full list of available rates and indices please see Appendix A) in order to protect the integrity of the methodology and calculation process and to address potential conflicts of interest. The role of the Oversight Committee is to provide an oversight function to review and provide challenge on all aspects of the methodology and calculation process and provide effective oversight of CF as the administrator of the Cryptocurrency Pricing Products.

## Membership

- The initial members of the Oversight Committee and its Chairman shall be appointed jointly by CF and CME with terms as specified in their Appointment Letters. Subsequent appointments shall be approved by the Oversight Committee. No individual may serve on the Oversight Committee for more than four consecutive years. The Chairman of the Oversight Committee shall be a CME Member.
- The Oversight Committee shall be comprised of at least five members, including at least:
  - (i) two who are representatives of CME (“**CME Members**”);
  - (ii) one who is a representative of CF (“**CF Member**”); and
  - (iii) two who bring expertise and industry knowledge relating to benchmark determination, issuance and operations.
- Any member of the Oversight Committee may be removed with or without cause jointly by CF and CME. A member may resign by giving at least three business day’s written notice of his or her intention to do so to the Chairman. Upon a resignation or removal, a replacement shall be considered as soon as practicable thereafter.

## Oversight Committee Meetings, Tasks and Authority

### *General*

- The Oversight Committee shall meet as often as the Chairman determines necessary to carry out its duties and responsibilities but no less frequently than quarterly and keep minutes of its proceedings.
- Meetings may be held in person or telephonically.
- A quorum of the Oversight Committee shall be a majority of its members. A motion shall pass upon approval from a majority of the members present; provided that at least one CME Member and one CF Member is present. Voting may also be conducted outside a meeting via telephone and/or electronic polling of members; provided approval is received by a majority of the current members of the Oversight Committee and by at least one CME Member and one CF Member.

### *Responsibilities*

- Reviewing on a quarterly basis or more frequently if necessary the determination of the Cryptocurrency Pricing Products and all other matters relating to such determination, including, without limitation, their:
  - a. Definition;
  - b. Setting;
  - c. Scope;
  - d. Methodology; and
  - e. Distribution.

The Oversight Committee shall be informed of changes to any of the matters set out above and shall approve any substantive changes to matters relating to points (d) and (e).

- Reviewing and ensuring CF's role as Administrator and Calculation Agent, that it maintains appropriate procedures and quality of management information for the monitoring and surveillance of the Cryptocurrency Pricing Products.
- Authorizing the appropriate response in the event that any CME CF Reference Rate publishes the prior day's rate three consecutive times.
- Participating in ongoing education pertaining to the Oversight Committee's responsibilities, including the material risks and other issues affecting the Cryptocurrency Pricing Products.
- Assessing the usage and significance of the Cryptocurrency Pricing Products and ensuring they remain effective and representative.

- Reviewing the Practice Standards for the Cryptocurrency Pricing Products at least on an annual basis and approving any substantive amendments.
- Reviewing reports on any complaints or concerns regarding the Cryptocurrency Pricing Products' relevance, resistance to manipulation, replicability, transparency and/or compliance with the applicable methodology and overseeing the related investigation and remedial actions, if any.
- Reviewing and approving the selection criteria applicable to Cryptocurrency exchanges that contribute data relating to the Cryptocurrency Pricing Products (the "**Constituent Exchanges**"), approving the Constituent Exchanges and the process by which relevant submissions are made.
- Approving the removal of any Constituent Exchanges; provided, however, in unusual and extreme circumstances, CF, as the administrator, may take emergency action to remove a Constituent Exchange to preserve the integrity of Cryptocurrency Pricing in accordance with the Practice Standards.
- Assessing potential conflicts of interest in the functioning and operation of the Cryptocurrency Pricing Products or any associated governance framework, policy or control process in accordance with the Cryptocurrency Pricing Products Conflicts of Interest Policy.
- Reviewing the adequacy of the control framework relating to the Cryptocurrency Pricing Products to assess their compliance with the International Organization of Securities Commissions Principles for Financial Benchmarks.
- Reviewing the results of any audit or other external review of the Cryptocurrency Pricing Products and providing oversight over the response and remediation efforts, if any, in response to such reviews.
- Reviewing this Charter at least on an annual basis and submitting any recommended changes to CF and CME for approval.

Approved on November 11, 2016

## Appendix A

### Full List of CME CF Cryptocurrency Pricing Products

#### CME CF Cryptocurrency Reference Rates

	CME CF Bitcoin Reference Rate	CME CF Ether-Dollar Reference Rate
<b>Ticker Symbol</b>	BRR	ETHUSD_RR
<b>Relevant Pair</b>	Bitcoin vs. U.S. Dollars	Ether vs. U.S. Dollars
<b>Effective Time</b>	4:00 p.m. London time	4:00 p.m. London time

#### CME CF Cryptocurrency Real Time Indices

	CME CF Bitcoin Real Time Index	CME CF Ether-Dollar Real Time Index
<b>Ticker Symbol</b>	BRTI	ETHUSD_RTI
<b>Relevant Pair</b>	Bitcoin vs. U.S. Dollars	Ether vs. U.S. Dollars
<b>Calculation Frequency</b>	Every second, 24 hours a day, every day	

# Notice and Disclaimer

CF Benchmarks Ltd is registered in England with registered number 11654816 and registered office at 25 Copthall Avenue, London EC2R 7BP, United Kingdom. CF Benchmarks is authorised by the UK Financial Conduct Authority as a registered Benchmark Administrator (FRN 847100).

This document and all of the information contained in it, including without limitation all methods, processes, concepts, text, data, graphs, charts (collectively, the "Information") is the property of CF Benchmarks Ltd or its licensors, direct or indirect suppliers or any third party involved in making or compiling any Information (collectively, with CF Benchmarks Ltd, the "Information Providers") and is provided for informational purposes only. The Information may not be reproduced or disseminated in whole or in part without prior written consent from CF Benchmarks Ltd.

The Information may not be used to create derivative works or to verify or correct other data or information without prior written consent from CF Benchmarks Ltd. For example (but without limitation), the Information may not be used to create indices, databases, risk models, analytics, software, or in connection with the issuing, offering, sponsoring, managing or marketing of any securities, portfolios, financial products or other investment vehicles utilizing or based on, linked to, tracking or otherwise derived from the Information or any other CF Benchmarks Ltd data, information, products or services.

The user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. CF BENCHMARKS SOEA NOT MAKE ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IT EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES (INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY, ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE INFORMATION.

Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall CF Benchmarks have any liability regarding any of the Information for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited, including without limitation (as applicable), any liability for death or personal injury to the extent that such injury results from the negligence or wilful default of itself, its servants, agents or sub-contractors.

None of CF Benchmarks Ltd's products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and none of CF Benchmarks Ltd's products or services is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Any use of or access to products, services or information of CF Benchmarks Ltd requires a license from CF Benchmarks Ltd.

CME Group and CME are trademarks of Chicago Mercantile Exchange Inc., used here with permission. All other trademarks are the property of their respective owners.